HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $50 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.5%

Neg 0% Neu 89.5% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $50 price target.